Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Mounjaro has now become available on the NHS for patients in the UK, meaning doctors will have a lot more work on their ...

Novo Nordisk A/S (NYSE:NVO) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks.

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Three months since Suzanne Harrington was prescribed the weight-loss jab Mounjaro, she opens up her diary and reveals all ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal antibody that binds to and inhibits activin receptor type-2B, with semaglutide ...